References
- [1] Borošková, Z., Dvorožňáková, E., Ševčíková, Z. (2003): Cellular immune reactions of mice with alveolar echinococcosis after albendazole therapy. Helminthologia, 40(1): 187–194
- [2] Bresson-Hadni, S., Vuitton, D. A., Bartholomot, D., Heyd, B., Godart, D., Meyer, J. P., Hrusovsky, S., Becker, M. C., Mantion, G., Lenys, D., Miguet, J. P. (2000): A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur. J. Gastroenterol. Hepatol., 12(3): 327–336 http://dx.doi.org/10.1097/00042737-200012030-00011
- [3] Dražilová, S., Kinčeková, J., Beňa, Ľ., Zachar, M., Švajdler, M., Zavacký, P., Jarčuska, P. (2011): Alveolar echinococcosis in patient after cadaveric kidney transplantation. Helminthologia, 48(4): 229–236. DOI: 10.2478/s11687-011-0032-4 http://dx.doi.org/10.2478/s11687-011-0032-4
- [4] Dvorožňáková, E., Hrčková, G., Borošková, Z., Velebný, S., Dubinský, P. (2004): Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis. Parasitol. Int., 53(4): 315–325. DOI:10.1016/j.parint.2004.05.001 http://dx.doi.org/10.1016/j.parint.2004.05.001
- [5] Dvorožňáková, E., Porubcová, J., Šnábel, V., Fedoročko, P. (2008): Immunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole. Parasitol. Res., 103(4): 919–929. DOI: 10.1007/s00436-008-1077-2 http://dx.doi.org/10.1007/s00436-008-1077-2
- [6] Dvorožňáková, E., Porubcová, J., Ševčíková, Z. (2009): Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol. Res., 105(4): 1067–1076. DOI: 10.1007/s00436-009-1520-z http://dx.doi.org/10.1007/s00436-009-1520-z
- [7] Dubinský, P., Svobodová, V., Turčeková, Ľ., Literák, I., Martínek, K., Reiterová, K., Kolářová, L., Klimesš, J., Mrlík, V. (1999): Echinococcus multilocularis in Slovak Republic: The first record in red foxes (Vulpes vulpes). Helminthologia, 36(2): 105–110
- [8] Eckert, J., Gemmell, M., Meslin, F., Pawlowski, Z. S. (2001): WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern. Paris: World Health Organization/ World Organization for Animal Health: 20–47
- [9] Emery, I., Liance, M., Leclerc, C. (1997): Secondary Echinococcus multilocularis infection in A/J mice: delayed metacestode development is associated with Th1 cytokine production. Parasite Immunol., 19(11): 493–503 http://dx.doi.org/10.1046/j.1365-3024.1997.d01-162.x
- [10] EASL — European Association for Study of the Liver (2011): EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J. Hepatol., 55(2): 245–264. DOI: 10.1016/j.jhep.2011.02.023 http://dx.doi.org/10.1016/j.jhep.2011.02.023
- [11] Godot, V., Harraga, S., Podoprigora, G., Liance, M., Bardonnet, K., Vuitton, D. A. (2003): IFN alpha-2a protects mice against a helminth infection of the liver and modulates immune responses. Gastroenterology, 124(5): 1441–1450. DOI:10.1016/S0016-5085(03)00273-7 http://dx.doi.org/10.1016/S0016-5085(03)00273-7
- [12] Jenne, L., Kilwinski, J., Radloff, P., Flick, W., Kern, P. (1998): Clinical efficacy of and immunologic alterations caused by interferon gamma therapy for alveolar echinococcosis. Clin. Infect. Dis., 26(2): 492–494. DOI: 10.1086/516316 http://dx.doi.org/10.1086/516316
- [13] Kern, P., Grüner, P., Wahlers, K. (2011): Diagnosis and course of echinococcal disease in the transplant setting. Transpl. Infect. Dis., 13(3): 217–221. DOI: 10.1111/ j.1399-3062.2011.00643.x http://dx.doi.org/10.1111/j.1399-3062.2011.00643.x
- [14] Kinčeková J., Auer H., Reiterová K., Dubinský P., Szilágyiová M., Lauko Ľ., Aspöck H. (2001): The first case of autochtonous human alveolar echinococcosis in the Slovak Republic. Mitt. Österr. Ges. Tropenmed. Parasitol., 23: 33–38
- [15] Liance, M., Ricard-Blum, S., Emery, I., Houin, R., Vuitton, D. A. (1998): Echinococcus multilocularis infection in mice: in vivo treatment with a low dose of IFN-gamma decreases metacestode growth and liver fibrogenesis. Parasite, 5(3): 231–237
- [16] Miterpáková, M., Dubinský, P., Reiterová, K., Stanko, M. (2006): Climate and enviromental factors influencing Echinococcus multilocularis ocurrence in the Slovak Republic. Ann. Agric. Environ. Med., 13(2): 235–442
- [17] Porubcová, J., Dvorožňáková, E., Ševčíková, Z. (2007): Immunomodulative effect of glucan and/or glucan supplemented with zinc in albendazole therapy for murine alveolar echinococcosis. Parasitol. Res., 101: 751–760. DOI: 10.10007/s00436-007-0545-4 http://dx.doi.org/10.1007/s00436-007-0545-4
- [18] Rigano, R., Profumo, E., Ioppolo, S., Notargiacomo, S., Ortona, E., Teggi, A., Siracusano, A. (1995): Immunological markers indicating the effectiveness of pharmacological treatment in human hydatid disease. Clin. Exp. Immunol., 102: 281–285. DOI: 10.1111/j.1365-2249.1995.tb03778.x http://dx.doi.org/10.1111/j.1365-2249.1995.tb03778.x
- [19] Schweiger, A. (2007): Human alveolar echinococcosis after fox population increase, Switzerland. Emerg. Infect. Dis., 13(6): 878–882 DOI: 10.3201/eid1306.061074 http://dx.doi.org/10.3201/eid1306.061074
- [20] Vuitton, D. A., Zhang, S. L., Yang, Y., Godot, V., Beurton, I., Mantion, G., Bresson-Hadni, S. (2006): Survival strategy of Echinococcus multilocularis in the human host. Parasitol. Int. 55:S51–S55 http://dx.doi.org/10.1016/j.parint.2005.11.007
- [21] Vuitton, D. A., Gottstein, B. (2010). Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay. J. Biomed. Biotechnol., 2010: 1–14 http://dx.doi.org/10.1155/2010/923193
- [22] Wéclawiack, H., Kamar, N., Mehrenberger, M., Guilbeau-Frugier, C., Modesto, A., Izopet, J., Ribes, D., Sallusto, F., Rostaing, L. (2008): Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol. Dial. Transplant., 23(3): 1043–1047 http://dx.doi.org/10.1093/ndt/gfm678